The present document describes a method for therapeutic indirect immunization of an optimally debulked human ovarian cancer patient having a CA125 antigen level in the blood above normal levels, comprising administering to said human patient a monoclonal antibody specific to CA125 antigen having at least a xenogeneic Fc region； an immune complex formed between CA125 antigen and said monoclonal antibody having at least a xenogeneic Fc region； or a combination thereof.
